Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reply to Correspondence

Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”

Byoung Kuk Jang

Clin Mol Hepatol. 2024;30(2):297-298. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0210

View: 985 Download: 10

Original Article

JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis

Li Xie, Hui Chen, Li Zhang, Yue Ma, Yuan Zhou, Yong-Yu Yang, Chang Liu, Yu-Li Wang, Ya-Jun Yan, Jia Ding, Xiao Teng, Qiang Yang, Xiu-Ping Liu, Jian Wu

Clin Mol Hepatol. 2024;30(2):206-224. Published online January 8, 2024

DOI: https://doi.org/10.3350/cmh.2023.0506

View: 1954 Download: 145 Crossref: 4

Editorial

JCAD, a new potential therapeutic target in cholestatic liver disease

Byoung Kuk Jang

Clin Mol Hepatol. 2024;30(2):166-167. Published online March 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0128

View: 1030 Download: 25 Crossref: 1

Letter to the Editor

Forms of cholangitis to be considered after SARS-CoV-2 infection

Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim

Clin Mol Hepatol. 2022;28(4):929-930. Published online September 8, 2022

DOI: https://doi.org/10.3350/cmh.2022.0260

View: 2195 Download: 56 Web of Science: 2 Crossref: 3

Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study

Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung

Clin Mol Hepatol. 2022;28(4):926-928. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0233

View: 2296 Download: 68 Web of Science: 2 Crossref: 3

Clinical and serological prognostic markers in primary biliary cholangitis

Markus Wilhelmi

Clin Mol Hepatol. 2021;27(2):360-361. Published online March 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0088

View: 3406 Download: 106

Review

Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea

Sook-Hyang Jeong

Clin Mol Hepatol. 2018;24(1):10-19. Published online January 5, 2018

DOI: https://doi.org/10.3350/cmh.2017.0066

View: 10757 Download: 281 Web of Science: 16 Crossref: 15

1 |

Viewed By 5589	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4803	MAFLD: How is it different from NAFLD?
Viewed By 4541	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3713	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3689	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 135	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 80	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 57	MAFLD: How is it different from NAFLD?

Search